Weight-loss drugs' impact on cancer risk revealed in new study

Weight-loss medications and bariatric surgery have both been found effective at helping people shed excess pounds — and now a new study explores their link to obesity-related cancer (ORC) risk.
Obesity is a known risk factor for certain types of cancers, and has also been shown to impact cancer survival.
Obesity-related cancers include multiple myeloma, meningioma, adenocarcinoma of esophagus; stomach, colorectal, liver or bile duct, gallbladder, pancreas, uterus, ovary, renal-cell kidney, thyroid, and postmenopausal breast cancer, according to the Centers for Disease Control and Prevention (CDC).
Semaglutide Found To Have Shocking Benefit For Liver Disease Patients In New Study
Researchers at Clalit Health Services in Tel Aviv, Israel, conducted an observational study of the medical records of 6,356 participants aged 24 and older who had obesity and diabetes, with no history of obesity-related cancer.
Between 2010 and 2018, half of the participants took GLP-1 receptor agonists (GLP-1 RAs) — injectable medications for obesity and type 2 diabetes — with at least six drug purchases within 12 months. The other half underwent bariatric metabolic surgery (BMS).
Read On The Fox News App
After adjusting for other factors, the researchers determined that ORC occurred in 5.62 cases per 1,000 person-years in those who had the surgery, and in 5.89 cases per 1,000 person-years among those who took GLP-1s.
Overall, the study determined that "the direct effect of GLP1-RAs compared to BMS on the risk for ORC beyond their effects on weight-loss is estimated as 41% relative risk reduction."
Here's Why Belly Fat Is More Common As We Age, And 3 Ways To Prevent It
The findings were published in the journal eClinicalMedicine.
"The results point at the existence of additional pathways beyond weight loss in which GLP-1RAs contribute to the decreased risk for obesity-related cancer," lead study author Yael Wolff Sagy, PhD, head of research at Clalit Health Services, told Fox News Digital.
Niketa Patel, professor of molecular medicine with the USF Health Morsani College of Medicine in Tampa, Florida, noted that obesity is associated with chronic inflammation.
"GLP1-RAs are shown to reduce inflammation and thus decrease the risk of developing ORC," she told Fox News Digital. (Patel was not involved in the study.)
"Bottom line: Obesity can cause certain cancers, and treatment of obesity with GLP1-RA reduces the risk of only obesity-related cancers."
Dr. Britta Reierson, MD, medical director of knownwell, a provider of metabolic health services, said there are several ways in which GLP-1 RAs could have cancer mitigation properties.
"First, the anti-inflammatory properties of these medications address a known risk factor for various cancers," the Minnesota-based doctor, who also was not part of the research, told Fox News Digital.
"Second, the metabolic regulation and improvement in metabolic health from these medications, including lowering blood glucose levels and decreasing insulin resistance, can reduce cancer risk."
Emerging evidence also suggests that GLP-1 RAs may have direct anti-tumor effects, Reierson noted — "potentially through modulation of immune responses and epigenetic changes (changes that occur to gene expression and are passed down to future generations)."
First Glp-1 Pill For Weight Loss, Diabetes Shows Success In Late-phase Trial
Research suggests that GLP-1 medications help reduce inflammation not just through weight loss, but also in other organs of the body, such as the heart, according to Dr. Susan Savery, MD, a board-certified obesity medicine and primary care physician with PlushCare, a virtual health platform offering primary care, therapy and weight management services.
"Over time, chronic inflammation can be a risk factor for cancer development, as it may damage cell DNA," San Francisco-based Savery, who was not involved in the study, told Fox News Digital.
"Our fat cells (adipose tissue) naturally produce inflammatory cells, and GLP-1 medications, similar to bariatric surgery, help reduce this inflammation by decreasing the amount of adipose tissue through weight loss."
The study did have some limitations, the researchers acknowledged.
"First, it is an observational study. It means that our comparison groups (persons who had surgery versus those who received GLP1-RAs) may still have some residual differences, despite our methodological efforts," Sagy told Fox News Digital.
"However, only this type of real-life observational study can provide the long follow-up period that is necessary to evaluate the risk of developing cancer, which often has very long latency periods."
Another limitation is that the primary drug included in the study was liraglutide (Saxenda, Victoza), with smaller numbers of people taking exenatide (Byetta) and dulaglutide (Trulicity).
"It will be important to evaluate the comparative effectiveness of the newer GLP1-RA drugs, which are expected to have a larger effect," Sagy said.
"Although the direction of the results is promising, we should wait and see if and how clinical guidelines will consider it."
Click Here To Sign Up For Our Health Newsletter
Reierson agreed that much more research is needed before GLP-1 RAs could ever be considered as cancer prevention options.
"Larger, randomized, controlled trials are necessary to confirm the observed effects and better understand the underlying mechanisms," she said.
"It will also be important to investigate the impact of GLP-1 RAs on different types of cancer and assess the long-term safety and potential side effects of using GLP-1 RAs as a cancer therapy."
Savery agrees that it's likely too early to predict FDA approval for cancer therapy, but noted that "weight reduction plays an important role in cancer prevention, and GLP-1s seem to offer an additional benefit through inflammation reduction."
For more Health articles, visit www.foxnews.com/health
While GLP-1 RAs are "wonderful tools" that can support people on weight-loss journeys, Savery pointed out that maintaining a healthy lifestyle through nutritious eating and regular physical activity is "the foundation for cancer prevention and better overall health."Original article source: Weight-loss drugs' impact on cancer risk revealed in new study

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

3 hours ago

• Yahoo

Who are the eight new vaccine advisers appointed by Robert F Kennedy?

Robert F Kennedy Jr, the US health secretary, named eight new vaccine advisers this week to a critical Centers for Disease Control and Prevention (CDC) panel after firing all 17 experts who had held the roles. New members of the panel include experts who complained about being sidelined, a high-profile figure who has spread misinformation and medical professionals who appear to have little vaccine expertise. Kennedy made the announcement on social media. 'All of these individuals are committed to evidence-based medicine, gold-standard science, and common sense,' Kennedy said in his announcement. 'They have each committed to demanding definitive safety and efficacy data before making any new vaccine recommendations.' Formally called the Advisory Committee on Immunization Practices (ACIP), the panel advises the CDC on how vaccines should be distributed. Those recommendations in effect determine the vaccines Americans can access. This week, Kennedy also removed the career officials typically tasked with vetting ACIP members and overseeing the advisory group, according to CBS News. Related: RFK Jr announces new panel of vaccine advisers after firing entire previous team Kennedy is a widely known vaccine skeptic who profited from suing vaccine manufacturers, has taken increasingly dramatic steps to upend US vaccine policy. 'ACIP is widely regarded as the international gold standard for vaccine decision-making,' said Helen Chu, one of the fired advisers, at a press conference with Patty Murray, a Democratic US senator. 'We cannot replace it with a process driven by one person's beliefs. In the absence of an independent, unbiased ACIP, we can no longer trust that safe and effective vaccines will be available to us and the people around us.' Arguably the most high-profile new member, Robert W Malone catapulted to stardom during the Covid-19 pandemic, appearing across rightwing media to criticize the Biden administration while describing himself as the inventor of mRNA technology. Messenger RNA technology powers the most widely used Covid-19 vaccines. While Malone was involved in very early experiments on the technology, researchers have said his role was limited. Malone's star rose quickly after appearing on the Joe Rogan podcast in 2022, where he and Rogan were criticized for spreading misinformation. On the show, Malone promoted the idea that both ivermectin and hydroxychloroquine could be possible treatments for Covid-19, but said research on the drugs was being suppressed. Ivermectin and hydroxychloroquine have not been shown to improve outcomes from Covid-19. 'Malone has a well-documented history of promoting conspiracy theories,' said Dr Jeffrey D Klausner, an epidemiologist and infectious disease expert at the University of Southern California, who recently told the New York Times he was in touch with Kennedy about his appointments. Kulldorff is a former Harvard professor of biostatistics and an infectious disease epidemiologist originally from Sweden. He said in an essay for the rightwing publication City Journal that he was fired because he refused to be vaccinated in line with the school policy. Like Malone, he rose to prominence during the pandemic as a 'Covid contrarian' who criticized the scientific consensus – views he said alienated him from his peers in the scientific community. He voiced his opposition to Covid-19 vaccine mandates and, in his essay, complained of being ignored by media and shadow-banned from Twitter. Kulldorff co-authored the Great Barrington Declaration, which called for limited closures instead of pandemic lockdowns before vaccines were available. The document became a touchstone for the American political right. Before the pandemic, Kulldorff studied vaccine safety and infectious disease, including co-authoring papers with members of CDC staff, such as on the Vaccine Safety Datalink. He was a member of the CDC's Covid Vaccine Safety Working Group in 2020, but said later he was fired because he disagreed with the agency's decision to pause Johnson & Johnson's Covid-19 vaccine and with Covid-19 vaccine mandates. He served on the Food and Drug Administration's (FDA) drug safety and risk management advisory committee around the same time. He has since enjoyed support from people already within the administration, including the Great Barrington Declaration co-author Dr Jay Bhattacharya, current head of the National Institutes of Health (NIH), and Dr Vinay Prasad, head of the Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research, which handles vaccines. Meissner is a professor of pediatrics at the Geisel School of Medicine at Dartmouth. He previously held advisory roles at the FDA and CDC, including ACIP from 2008-2012. In 2021, Meissner co-wrote an editorial with Dr Marty Makary, now the head of the FDA, which criticized mask mandates for children. In April, he was listed as an external adviser to ACIP on the respiratory syncytial virus (RSV) committee. Notably, Meissner is listed in a new conflicts of interest tool launched by the health department in March. Kennedy had criticized the fired ACIP members as 'plagued with persistent conflicts of interest'. 'He's a card-carrying infectious disease person who knows the burden of these diseases, and he knows the risk and the benefit,' Dr Kathryn Edwards told CBS News. Edwards previously served as chair of the FDA's vaccine advisory panel. Pebsworth is a nurse and the former consumer representative on the FDA's vaccine advisory committee. She is also the Pacific regional director for the National Association of Catholic Nurses, according to Kennedy's announcement. In 2020, Pebsworth spoke at the public comment portion of an FDA advisory panel meeting on Covid-19 vaccines. There, she identified herself as the volunteer research director for the National Vaccine Information Center (NVIC), 'and the mother of a child injured by his 15-month well-baby shots in 1998'. The NVIC is widely viewed as an anti-vaccine advocacy organization 'whose founder Barbara Lou Fisher must be considered a key figure of the anti-vaccine movement', according to an article from 2023 on how to counter anti-vaccine misinformation. Levi is a professor of operations management at the MIT Sloan School of Management who Kennedy described as an 'expert in healthcare analytics, risk management and vaccine safety'. In 2021, he opposed Covid-19 booster shot approval during the public comment portion of an FDA advisory committee hearing. In 2022, he wrote an article calling for EMS calls to be incorporated into vaccine safety data, arguing that cardiovascular side-effects could be undercounted – an article that later required correction. The potential effects of Covid-19 vaccines on heart health have been a focal point of right-leaning criticism. Last month, Levi was criticized for publishing a pre-print paper – a paper without peer review – that he co-authored with Dr Joseph Ladapo, the Florida surgeon general, a vaccine skeptic. The paper alleged that people who took the Pfizer Covid-19 vaccine were more likely to die than those who received the Moderna vaccine. Kennedy described Ross as 'a Clinical Professor of Obstetrics and Gynecology at George Washington University and Virginia Commonwealth University, with a career spanning clinical medicine, research, and public health policy'. However, as first reported by CBS News, Ross's name does not appear in faculty directories for either school. A spokesperson for George Washington University told the outlet that Ross did work as a clinical professor, but 'has not held a faculty appointment … since 2017'. A spokesperson for Virginia Commonwealth University described Ross as 'an affiliate faculty member' at a regional hospital system in the Capitol region. He is also listed as a partner at Havencrest Capital Management, as a board member of 'multiple private healthcare companies'. Hibbeln is a California-based psychiatrist who previously served as acting chief for the section of nutritional neurosciences at the NIH. He describes himself as an expert on omega-3, a fatty acid found in seafood. He also serves on the advisory council of a non-profit that advocates for Americans to eat more seafood. He practices at Barton Health, a hospital system in Lake Tahoe, California. His work influenced US public health guidelines on fish consumption during pregnancy. Pagano is an emergency medicine physician from Los Angeles 'with over 40 years of clinical experience', and a 'strong advocate for evidence-based medicine', according to Kennedy.

New York Post

11 hours ago

• New York Post

Why Ozempic users should be extra careful during heatwaves

Talk about melting the weight off. Summer may be filled with beach days and barbecues, but it can also bring blistering temperatures. This week, millions of Americans — including New Yorkers — are bracing for what forecasters are calling a 'very sweaty' heatwave. People who are on GLP-1s need to be on particularly high alert amidst the high degrees. New Africa – And people who are on weight loss drugs like Ozempic, Wegovy and Mounjaro need to be on particularly high alert amidst the high degrees. That's because these drugs work by suppressing appetite, which means they can wind up curbing thirst as well. This, in turn, can unwittingly lead to dehydration — a dangerous condition that can cause dizziness, headaches, low blood pressure, blurred vision, kidney problems and, in extreme cases, fatal heatstroke. Since eating normally stimulates saliva flow, eating less while on Ozempic can mean less stimulation to the salivary glands, which can in turn lead to dry mouth — another symptom of dehydration left unchecked. And if you've heard about Ozempic teeth, you know some of the most common side effects of GLP-1s pose their own dangers during a heatwave. 'You'll need to be extra careful about hydration during hot weather as these medications often cause nausea, vomiting or diarrhea — all of which can lead to fluid loss,' nutritional therapist Deborah Grayson told The Daily Mail. 'This is particularly important for new users of the weight loss medication, whose bodies are still adjusting.' 'You'll need to be extra careful about hydration during hot weather as these medications often cause nausea, vomiting or diarrhea — all of which can lead to fluid loss,' Grayson said. millaf – To remain vigilant, Grayson recommends the following: Drink plenty of water, even if you don't feel thirsty Put a timer on to remind you to hydrate Avoid alcohol and caffeine Avoid being outdoors during peak heat hours Eat easy-to-digest foods such as those on the BRAT diet In addition to suppressing thirst and potentially inducing vomiting/diarrhea, GLP-1s could mess with your body's ability to regulate body temperature, making it harder to tolerate heat. This is all the more reason to drink lots of water — sprinkle some electrolytes into the mix to stay hydrated longer. Use urine as your barometer — light yellow means you're in the clear, whereas darker colors are a bad sign. And avoid physical exertion, especially outside. It might be excruciatingly hot, but perhaps the heatwave is a good excuse to stay on your Ozempic butt for a bit.

Yahoo

16 hours ago

• Yahoo

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

By Bhanvi Satija (Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite. The initial Wall Street estimates for muscle-preserving therapies follow promising mid-stage results from experimental drugs developed by Regeneron and Scholar Rock. Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week. Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to preserve muscle will grow with the use of GLP-1 drugs for obesity, said TD Cowen analyst Tyler Van Buren. Doctors have raised concerns that patients may experience a decrease in overall strength due to muscle loss associated with Zepbound and Wegovy, while experts suggest that more muscle can help patients maintain long-term weight loss. Van Buren said that the first such treatment could launch by 2028, although regulatory challenges remain because these treatments must demonstrate additional health benefits to secure approval. "We believe quality of weight loss and lean mass preservation ... is far too important for long-term health outcomes to be ignored and that this will be figured out," Van Buren said. Some of the new drugs target the myostatin protein, which is associated with muscle growth, and are expected to see broader use due to their superior safety profile, capturing the majority of the market share, Van Buren said. Other drugs target activin, a protein with multiple biological functions. Van Buren said that activin-based drugs will be reserved for patients at higher risk of losing strength, forecasting sales of about $5 billion by 2035.